Overview
Francesco Schena practices in Bari, Italy. Mr. Schena is rated as an Elite expert by MediFind in the treatment of IgA Nephropathy. His top areas of expertise are IgA Nephropathy, Glomerulonephritis, Chronic Kidney Disease, Lupus Nephritis, and Kidney Transplant.
His clinical research consists of co-authoring 118 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 39 articles in the study of IgA Nephropathy.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- GlomerulonephritisMr. Schena isElite. Learn about Glomerulonephritis.
- IgA NephropathyMr. Schena isElite. Learn about IgA Nephropathy.
- Advanced
- Chronic Kidney DiseaseMr. Schena isAdvanced. Learn about Chronic Kidney Disease.
- Kidney TransplantMr. Schena isAdvanced. Learn about Kidney Transplant.
- Lupus NephritisMr. Schena isAdvanced. Learn about Lupus Nephritis.
- Experienced
- Alport SyndromeMr. Schena isExperienced. Learn about Alport Syndrome.
- Autosomal Dominant Polycystic Kidney Disease
- End-Stage Renal Disease (ESRD)Mr. Schena isExperienced. Learn about End-Stage Renal Disease (ESRD).
- HypertensionMr. Schena isExperienced. Learn about Hypertension.
- Membranoproliferative Glomerulonephritis
- Minimal Change DiseaseMr. Schena isExperienced. Learn about Minimal Change Disease.